Cancer CRISPR Screens In Vivo
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
CRISPR screening is a powerful toolset for investigating diverse biological processes. Most CRISPR screens to date have been performed with in vitro cultures or cellular transplant models. To interrogate cancer in animal models that more closely recapitulate the human disease, autochthonous direct in vivo CRISPR screens have recently been developed that can identify causative drivers in the native tissue microenvironment. By empowering multiplexed mutagenesis in fully immunocompetent animals, direct in vivo CRISPR screens enable the rapid generation of patient-specific avatars that can guide precision medicine. This review discusses the current status of in vivo CRISPR screens in cancer, and offers perspectives on future applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994 · cited 1×
“While in vitro studies are valuable for identifying cell-intrinsic properties of cancer cells and potential therapeutic windows (Figure 2A, Key Figure), they cannot address problems involving complex interactions between multiple cell types that reflect the bona fide nature of cancer as an organ, instead of a collecti…”
BackgroundVogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage
Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A., & Liu, D. R. (2016) · Nature · doi:10.1038/nature17946 · Cited by 5,437 · cited 1×
“In addition to its canonical use for targeted gene knockouts [5,6], CRISPR has been reengineered for a variety of purposes including transcriptional activation [7,8], transcriptional repression [9], histone modification [10], base editing [11,12], DNA methylation [13–15], and genome architecture manipulation [16].”
BackgroundGenome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression
Qi, L. S., Larson, M. H., Gilbert, L. A., Doudna, J. A., Weissman, J. S., Arkin, A. P., & Lim, W. A. (2013) · Cell · doi:10.1016/j.cell.2013.02.022 · Cited by 5,016 · cited 1×
“In addition to its canonical use for targeted gene knockouts [5,6], CRISPR has been reengineered for a variety of purposes including transcriptional activation [7,8], transcriptional repression [9], histone modification [10], base editing [11,12], DNA methylation [13–15], and genome architecture manipulation [16].”
BackgroundOptimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
Doench, J. G., Fusi, N., Sullender, M., Hegde, M., Vaimberg, E. W., Donovan, K. F., Smith, I., Tothova, Z., Wilen, C., Orchard, R., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3437 · Cited by 4,637 · cited 1×
“Unlike RNAi screens, CRISPR generates precise mutations or complete knockouts instead of partial gene knockdown or silencing, which has been shown to facilitate higher between-construct concordance and lower off-target rates [21,22].”
BackgroundProgrammable base editing of A•T to G•C in genomic DNA without DNA cleavage
Gaudelli, N. M., Komor, A. C., Rees, H. A., Packer, M. S., Badran, A. H., Bryson, D. I., & Liu, D. R. (2017) · Nature · doi:10.1038/nature24644 · Cited by 4,184
CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes
Gilbert, L. A., Larson, M. H., Morsut, L., Liu, Z., Brar, G. A., Torres, S. E., Stern-Ginossar, N., Brandman, O., Whitehead, E. H., Doudna, J. A., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.044 · Cited by 3,696 · cited 1×
“In addition to its canonical use for targeted gene knockouts [5,6], CRISPR has been reengineered for a variety of purposes including transcriptional activation [7,8], transcriptional repression [9], histone modification [10], base editing [11,12], DNA methylation [13–15], and genome architecture manipulation [16].”
BackgroundSpatially resolved, highly multiplexed RNA profiling in single cells
Chen, K. H., Boettiger, A. N., Moffitt, J. R., Wang, S., & Zhuang, X. (2015) · Science · doi:10.1126/science.aaa6090 · Cited by 2,969 · cited 1×
“To further provide spatial information, multiplexed fluorescent in situ hybridization (MERFISH) [71] could potentially be adapted for the purpose of sequencing sgRNA pools directly in tissue sections.”
BackgroundGenetic screens in human cells using the CRISPR-Cas9 system
Wang, T., Wei, J. J., Sabatini, D. M., & Lander, E. S. (2014) · Science · doi:10.1126/science.1246981 · Cited by 2,856
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
Konermann, S., Brigham, M. D., Trevino, A. E., Joung, J., Abudayyeh, O. O., Barcena, C., Hsu, P. D., Habib, N., Gootenberg, J. S., Nishimasu, H., et al. (2015) · Nature · doi:10.1038/nature14136 · Cited by 2,825
Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation
Gilbert, L. A., Horlbeck, M. A., Adamson, B., Villalta, J. E., Chen, Y., Whitehead, E. H., Guimaraes, C., Panning, B., Ploegh, H. L., Bassik, M. C., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.029 · Cited by 2,728 · cited 1×
“In addition to its canonical use for targeted gene knockouts [5,6], CRISPR has been reengineered for a variety of purposes including transcriptional activation [7,8], transcriptional repression [9], histone modification [10], base editing [11,12], DNA methylation [13–15], and genome architecture manipulation [16].”
BackgroundPD-L1 expression as a predictive biomarker in cancer immunotherapy
Patel, S. P., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0983 · Cited by 2,291
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Gordon, S. R., Maute, R. L., Dulken, B. W., Hutter, G., George, B. M., McCracken, M. N., Gupta, R., Tsai, J. M., Sinha, R., Corey, D., et al. (2017) · Nature · doi:10.1038/nature22396 · Cited by 2,247
CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling
Platt, R. J., Chen, S., Zhou, Y., Yim, M. J., Swiech, L., Kempton, H. R., Dahlman, J. E., Parnas, O., Eisenhaure, T. M., Jovanovic, M., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.014 · Cited by 2,001
Self-citationDixit, A., Parnas, O., Li, B., Chen, J., Fulco, C. P., Jerby-Arnon, L., Marjanovic, N. D., Dionne, D., Burks, T., Raychowdhury, R., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.038 · Cited by 1,863
Identification and characterization of essential genes in the human genome
Wang, T., Birsoy, K., Hughes, N. W., Krupczak, K. M., Post, Y., Wei, J. J., Lander, E. S., & Sabatini, D. M. (2015) · Science · doi:10.1126/science.aac7041 · Cited by 1,617
High-throughput functional genomics using CRISPR-Cas9
Shalem, O., Sanjana, N. E., & Zhang, F. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3899 · Cited by 1,233 · cited 1×
“Following in the footsteps of RNAi screens, the modularity of CRISPR has naturally lent itself to high-throughput screening approaches [17].”
BackgroundEditing DNA Methylation in the Mammalian Genome
Liu, X. S., Wu, H., Ji, X., Stelzer, Y., Wu, X., Czauderna, S., Shu, J., Dadon, D., Young, R. A., & Jaenisch, R. (2016) · Cell · doi:10.1016/j.cell.2016.08.056 · Cited by 1,224
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
Manguso, R. T., Pope, H. W., Zimmer, M. D., Brown, F. D., Yates, K. B., Miller, B. C., Collins, N. B., Bi, K., LaFleur, M. W., Juneja, V. R., et al. (2017) · Nature · doi:10.1038/nature23270 · Cited by 1,147 · cited 1×
“Multiple in vivoCRISPR screens have since been performed to identify tumor suppressors [42–44], oncogenes [45], synthetically lethal genes [46], and regulators of cancer immunotherapy, in both two-cell type (2-CT) coculture systems [47] and transplant tumor models [48], among others.”
BackgroundPooled CRISPR screening with single-cell transcriptome readout.
Datlinger, P., Rendeiro, A. F., Schmidl, C., Krausgruber, T., Traxler, P., Klughammer, J., Schuster, L. C., Kuchler, A., Alpar, D., & Bock, C. (2017) · Nature Methods · doi:10.1038/nmeth.4177 · Cited by 1,096
Biological and therapeutic impact of intratumor heterogeneity in cancer evolution
McGranahan, N., & Swanton, C. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.12.001 · Cited by 1,077 · cited 1×
“In addition to cell-type heterogeneity and microenvironmental variations, intratumoral heterogeneity is often characterized by distinct subclonal mutation signatures that differentially influence cellular behavior [63].”
BackgroundMultiplex gene editing by CRISPR–Cpf1 using a single crRNA array
Zetsche, B., Heidenreich, M., Mohanraju, P., Fedorova, I., Kneppers, J., DeGennaro, E. M., Winblad, N., Choudhury, S. R., Abudayyeh, O. O., Gootenberg, J. S., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.3737 · Cited by 926
Identification of essential genes for cancer immunotherapy
Patel, S. J., Sanjana, N. E., Kishton, R. J., Eidizadeh, A., Vodnala, S. K., Cam, M., Gartner, J. J., Jia, L., Steinberg, S. M., Yamamoto, T. N., et al. (2017) · Nature · doi:10.1038/nature23477 · Cited by 870 · cited 1×
“Multiple in vivoCRISPR screens have since been performed to identify tumor suppressors [42–44], oncogenes [45], synthetically lethal genes [46], and regulators of cancer immunotherapy, in both two-cell type (2-CT) coculture systems [47] and transplant tumor models [48], among others.”
BackgroundDevelopment and function of human innate immune cells in a humanized mouse model
Rongvaux, A., Willinger, T., Martinek, J., Strowig, T., Gearty, S. V., Teichmann, L. L., Saito, Y., Marches, F., Halene, S., Palucka, A. K., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.2858 · Cited by 789 · cited 1×
“The development and application of humanized mice [60] has helped to bridge this gap in part, particularly with regard to innate immunity, although complete humanization of the full immune system remains to be seen.”
BackgroundDissecting Immune Circuits by Linking CRISPR-Pooled Screens with Single-Cell RNA-Seq
Jaitin, D. A., Weiner, A., Yofe, I., Lara-Astiaso, D., Keren-Shaul, H., David, E., Salame, T. M., Tanay, A., van Oudenaarden, A., & Amit, I. (2016) · Cell · doi:10.1016/j.cell.2016.11.039 · Cited by 777
CRISPR-mediated direct mutation of cancer genes in the mouse liver
Xue, W., Chen, S., Yin, H., Tammela, T., Papagiannakopoulos, T., Joshi, N. S., Cai, W., Yang, G., Bronson, R., Crowley, D. G., et al. (2014) · Nature · doi:10.1038/nature13589 · Cited by 776 · cited 1×
“In the liver, hydrodynamic injection of sgRNA-containing plasmids into the tail veins of Cas9 mice was sufficient to induce multiplexed mutagenesis in hepatocytes [49], while in the lung intratracheal delivery of sgRNA-carrying lentiviruses was able to induce mutagenesis directly in Cas9-expressing lung epithelial cel…”
BackgroundSelf-citationIn vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9
Swiech, L., Heidenreich, M., Banerjee, A., Habib, N., Li, Y., Trombetta, J., Sur, M., & Zhang, F. (2015) · Nature Biotechnology · doi:10.1038/nbt.3055 · Cited by 772 · cited 1×
“use of adenoassociated viruses (AAVs), direct mutagenesis in the mouse brain was also shown to be feasible [51].”
BackgroundWang, T., Yu, H., Hughes, N. W., Liu, B., Kendirli, A., Klein, K., Chen, W. W., Lander, E. S., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.01.013 · Cited by 632
Applications of the CRISPR-Cas9 system in cancer biology
Sánchez-Rivera, F. J., & Jacks, T. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3950 · Cited by 405
Combinatorial CRISPR–Cas9 screens for de novo mapping of genetic interactions
Shen, J. P., Zhao, D., Sasik, R., Luebeck, J., Birmingham, A., Bojorquez-Gomez, A., Licon, K., Klepper, K., Pekin, D., Beckett, A. N., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4225 · Cited by 359 · cited 1×
“In cancer, CRISPR screens have been performed to identify genes involved in a wide variety of processes [23], including regulators of drug resistance [24–28], synergistic and synthetic lethal interactions [29,30], regulators of PD-L1 expression [31], and essential genes [32–34] (Figure 1).”
BackgroundManipulation of nuclear architecture through CRISPR-mediated chromosomal looping
Morgan, S. L., Mariano, N. C., Bermudez, A., Arruda, N. L., Wu, F., Luo, Y., Shankar, G., Jia, L., Chen, H., Hu, J.-F., et al. (2017) · Nature Communications · doi:10.1038/ncomms15993 · Cited by 279
Zhou, H., Liu, J., Zhou, C., Gao, N., Rao, Z., Li, H., Hu, X., Li, C., Yao, X., Shen, X., et al. (2018) · Nature Neuroscience · doi:10.1038/s41593-017-0060-6 · Cited by 276 · cited 1×
“Additionally, the application of dCas9-activator mice could enable the functional identification of oncogenes directly in vivo, providing an orthogonal perspective to preexisting tumor suppressor screens [67].”
Background
Cited by
The BioGRID interaction database: 2019 update
Oughtred, R., Stark, C., Breitkreutz, B.-J., Rust, J., Boucher, L., Chang, C., Kolas, N., O’Donnell, L., Leung, G., McAdam, R., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1079 · Cited by 1,473
CRISPR in cancer biology and therapy
Katti, A., Diaz, B. J., Caragine, C. M., Sanjana, N. E., & Dow, L. E. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00441-w · Cited by 424
A new era in functional genomics screens
Przybyla, L., & Gilbert, L. A. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00409-w · Cited by 281
Strategies to enhance CAR-T persistence
Liu, Y., An, L., Huang, R., Xiong, J., Yang, H., Wang, X., & Zhang, X. (2022) · Biomarker Research · doi:10.1186/s40364-022-00434-9 · Cited by 97
“The CRISPR mediated functional genome-wide screening platform has become an excellent tool for meticulously discovering new gene functions and molecular mechanisms [186, 187].”
MethodHigh-Throughput CRISPR Screening in Hematological Neoplasms
Ancos-Pintado, R., Bragado-García, I., Morales, M. L., García-Vicente, R., Arroyo-Barea, A., Rodríguez-García, A., Martínez-López, J., Linares, M., & Hernández-Sánchez, M. (2022) · Cancers · doi:10.3390/cancers14153612 · Cited by 15
“On the other hand, indirect in vivo screens consist on the transplantation of pre-edited cells by the sgRNA library into an animal [107].”
Background
Metadata
- Authors
- Chow, R. D., & Chen, S.
- Venue
- Trends in Cancer
- Publisher
- Elsevier BV
- Published
- 2018-05
- Volume
- 4
- Issue
- 5
- Pages
- 349-358
- ISSN
- 2405-8025 (ISSN-L)
- 2405-8033
- OpenAlex
- W2794495801
- Cited by
- 119
- References
- 36
- FWCI
- 0.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.